未登录 Endoscopic and histologic results from the UNITI Jr study of ustekinumab in paediatric Crohn's Disease UNITI Jr研究：乌司奴单抗治疗儿童克罗恩病的内镜及组织学结果 De Greef, E.; Turner, D.; Kierkus, J.; Korczowski, B.; Meglicka, M.; Russell, R. K.; Cohen, S.; Hyams, J.; Griffiths, A.; Rosh, J.; Strauss, R.; Van Limbergen, E.; Adedokun, O.; Kim, L.; Branigan, P.; Volger, S.; Cheng, E. 分享 收藏
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease 血清蛋白谱在阿达木单抗和乌司奴单抗治疗中度至重度活动性克罗恩病中存在差异 Venkat, Swati; Zeeman, Martha; Hart, Amy; Bhagat, Sunita; Galbraith, David A.; Hoops, Timothy; Ufberg, Paul J.; Izanec, James; Freeman, Tom C.; Mcrae, Bradford; Shinzaki, Shinichiro; Jairath, Vipul; Panaccione, Remo; Sands, Bruce E.; Branigan, Patrick 分享 收藏
Impact of Subcutaneous Guselkumab Induction Therapy on Molecular Inflammation in Patients With Ulcerative Colitis: Results From the Phase 3 ASTRO Study 皮下注射古塞库单抗诱导治疗对溃疡性结肠炎患者分子炎症的影响：ASTRO III期研究结果 Venkat, Swati; Sridhar, Sunandini; Shaikh, Barbara; Sohn, Klebea; Liu, Jared; Sisk, Christopher; McRae, Bradford; Alvarez, Yelinia; Baker, Thomas; Germinaro, Matthew; Allegretti, Jessica R.; Long, Millie D.; Rubin, David T.; Peyrin-Biroulet, Laurent; Hart, Amy; Branigan, Patrick 分享 收藏
Molecular Differentiation of Guselkumab and Ustekinumab in Moderately to Severely Active Crohn's Disease: Post Hoc Analysis of the GALAXI 2 and 3 Phase 3 Studies 中度至重度活动性克罗恩病中 Guselkumab 与 Ustekinumab 的分子差异：GALAXI 2 和 3 III 期研究的回顾性分析 Richards, Dylan; Sohn, Klebea; Zeeman, Martha; Patel, Ruchi; McRae, Bradford; Terry, Nat A.; Vetter, Marion L.; Reinisch, Walter; Cua, Daniel; Branigan, Patrick 分享 收藏
Clinical response trajectories identify distinct subpopulations of ulcerative colitis patients and are linked to disease outcome across different therapy classes. Patient level analysis of 2378 participants from 6 randomized controlled trials in moderate-severe UC representing 8 different mechanisms of action. Schreiber, S. W.; Mueller-Breckenridge, A.; Cheng, J.; Wu, C.; Jelinsky, S. A.; Liu, J.; Agueusop, I; Freitag-Wolf, S.; Hall, A.; Baribaud, F.; El Houjajji, C.; Paun, A.; Mcbride, J.; Branigan, P.; Hart, A.; Waterworth, D.; Gale, J.; Woolcott, J. C.; Flechsenhar, K.; Rawlings, C. A.; Candela, N.; Yajnik, V; Krawczak, M.; Thakker, P.; Hecht, P. 分享 收藏
Comparison of pharmacodynamic and mechanistic response of guselkumab intravenous and subcutaneous induction in moderately to severely active Crohn's disease: molecular analysis of the GRAVITI and GALAXI Phase 3 studies Richards, D.; Patel, R.; Sohn, K.; Hart, A.; Lee, T.; Liu, J.; Sisk, C.; Olurinde, M.; Terry, N.; Mcrae, B.; Reinisch, W.; Feagan, B.; Steinwurz, F.; Panaccione, R.; D'Haens, G.; Branigan, P. 分享 收藏
DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis Hart, A.; Sridhar, S.; Venkat, S.; Huang, K. H. G.; Yarandi, S.; Germinaro, M.; Vetter, M. L.; Rubin, D. T.; Dignass, A.; Cua, D.; Freeman, T.; Waterworth, D.; Mcrae, B.; Verstockt, B.; Branigan, P. 分享 收藏
Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study Sridhar, S.; Hart, A.; Venkat, S.; Huang, K. H. G.; Yarandi, S.; Germinaro, M.; Vetter, M.; Rubin, D. T.; Dignass, A.; Cua, D.; Freeman, T.; Waterworth, D.; Mcrae, B.; Verstockt, B.; Branigan, P. 分享 收藏
Guselkumab Decreases Key Cellular Inflammatory Processes Across Ileum and Colon Tissue in Crohn's Disease Richards, Dylan; Venkat, Swati; Ruane, Darren; Zeeman, Martha; Terry, Natalie A.; Vetter, Marion; Gomez, Mario; Cua, Daniel; Freeman, Tom C.; Mcrae, Bradford; Feagan, Brian G.; Reinisch, Walter; Branigan, Patrick 分享 收藏
Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study Panes, Julian; Dignass, Axel; Hisamatsu, Tadakazu; Yarandi, Shadi; Huang, Kuan-Hsiang G.; Germinaro, Matthew; Sridhar, Sunandini; Branigan, Patrick; Wilson, Rebbecca; Zhang, Hongyan; Magro, Fernando; Jairath, Vipul; Feagan, Brian G.; Lichtenstein, Gary R.; Rubin, David T.; Sands, Bruce E. 分享 收藏
GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS GUSELKUMAB诱导恢复中度至重度活动性溃疡性结肠炎的肠道免疫稳态并促进上皮修复 Sridhar, S.; Hart, A.; Venkat, S.; Ruane, D.; Horowitz, D.; Lee, T.; Waterworth, D.; Huang, K. H. G.; Germinaro, M.; Vetter, M.; Cua, D.; Freeman, T. C.; Sisk, C.; Mcrae, B.; Verstockt, B.; Rubin, D. T.; Sands, B. E.; Branigan, P. 分享 收藏
GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY Guselkumab和Golimumab联合诱导治疗在溃疡性结肠炎中可导致早期局部组织愈合，并通过Guselkumab维持治疗得到持续。 Richards, D.; Vetter, M.; Germinaro, M.; Verstockt, B.; Atreya, R.; Panes, J.; Sands, B. E.; Feagan, B.; Mcrae, B.; Cua, D.; Branigan, P.; Freeman, T. C. 分享 收藏
Deep Learning Models Capture Histological Disease Activity in Crohn's Disease and Ulcerative Colitis with High Fidelity Rymarczyk, Dawid; Schultz, Weiwei; Borowa, Adriana; Friedman, Joshua R.; Danel, Tomasz; Branigan, Patrick; Chalupczak, Michal; Bracha, Anna; Krawiec, Tomasz; Warchol, Michal; Li, Katherine; De Hertogh, Gert; Zielinski, Bartosz; Ghanem, Louis R.; Stojmirovic, Aleksandar 分享 收藏
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus Cesaroni, Matteo; Seridi, Loqmane; Loza, Matthew J.; Schreiter, Jessica; Sweet, Kristen; Franks, Carol; Ma, Keying; Orillion, Ashley; Campbell, Kim; M. Gordon, Robert; Branigan, Patrick; Lipsky, Peter; van Vollenhoven, Ronald; Hahn, Bevra H.; Tsokos, George C.; Chevrier, Marc; Rose, Shawn; Baribaud, Frederic; Jordan, Jarrat 分享 收藏
The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis anti-interleukin-33受体单克隆抗体CNTO 7160在健康受试者和哮喘或特应性皮炎患者中的首次人体研究 Nnane, Ivo; Frederick, Bart; Yao, Zhenling; Raible, Donald; Shu, Cathye; Badorrek, Philipp; van den Boer, Maarten; Branigan, Patrick; Duffy, Karen; Baribaud, Frederic; Fink, Damien; Yang, Tong-Yuan; Xu, Zhenhua 分享 收藏
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study Gordon, Kenneth B.; Armstrong, April W.; Foley, Peter; Song, Michael; Shen, Yaung-Kaung; Li, Shu; Munoz-Elias, Ernesto J.; Branigan, Patrick; Liu, Xuejun; Reich, Kristian 分享 收藏
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Reich, Kristian; Armstrong, April W.; Langley, Richard G.; Flavin, Susan; Randazzo, Bruce; Li, Shu; Hsu, Ming-Chun; Branigan, Patrick; Blauvelt, Andrew 分享 收藏
Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study Silkoff, Philip E.; Flavin, Susan; Gordon, Robert; Loza, Mathew J.; Sterk, Peter J.; Lutter, Rene; Diamant, Zuzana; Turner, Ronald B.; Lipworth, Brian J.; Proud, David; Singh, Dave; Eich, Andreas; Backer, Vibeke; Gern, James E.; Herzmann, Christian; Halperin, Scott A.; Mensinga, Tjeert T.; Del Vecchio, Alfred M.; Branigan, Patrick; San Mateo, Lani; Baribaud, Frederic; Barnathan, Elliot S.; Johnston, Sebastian L. 分享 收藏
Sustained response following withdrawal of guselkumab treatment correlates with reduced Th17 and Th22 effector cytokine levels Branigan, P.; Liu, X.; Chen, Y.; Scott, B.; Yao, Z.; Li, S.; Wasfi, Y.; Song, M.; Campbell, K.; Munoz-Elias, E. 分享 收藏
分享 收藏
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
